One more new generic coming on to the market for the treatment of Alzheimer's, after FDA approval, which is pending. Patent expires December 2008 but this article states that J and J will appeal? It sounds like by the time all the red tape is cleared here that it just might be around the expiration of the patent date when the generic version just might get to market. BD
Barr Pharmaceuticals Inc. (BRL) said a federal court has invalidated a patent that clears the way for the generic-drug maker to sell its version of Johnson & Johnson (JNJ) Alzheimer's drug Razadyne. Barr said the ruling effectively end the 30-month stay against the company's generic version. The judge also denied a temporary restraining order sought by J&J to stop Barr from launching its generic. Razadyne, which had total sales of $214 million in the year ended June 30, is for mild to moderate dementia in Alzheimer's patients. Barr says it will now begin marketing the drugs as soon as it receives final approval from the Food and Drug Administration. The company got tentative approval in May 2007.
0 comments :
Post a Comment